Abstract
Purpose
Although BRCA1 gene mutations have been associated with breast cancer, BRCA1 mutations have been also involved in other functions. Thrombosis and coagulation are novel mechanisms recently associated with cancer. The aims of the present study were (a) to evaluate, using proteomics, if BRCA1 mutation carriers have a different plasma proteins expression related to thrombosis and coagulation profile than non-mutant BRCA1 women and (b) to analyze if the expression of these proteins may be different among BRCA1 mutation carriers with and without breast cancer.
Methods
Proteomic study was based on 2-dimensional electrophoresis and mass spectrometry. The study was performed in 10 BRCA1 non-mutant controls and 21 women with BRCA1 mutations (with breast cancer (n = 8) and breast cancer-free (n = 13)), all of them free of family history or diagnosis of ovarian cancer.
Results
Proteomic study showed that fibrinogen gamma chain isotypes 2 and 3, serotransferrin isotype 4, and convertase C3/C5 isotypes 1–5 were significantly increased in plasma from BRCA1 mutation carriers with respect to BRCA1 non-mutant controls. Plasma levels of alpha-1 antitrypsin isotypes 2–5, apolipoprotein A-IV, and vitamin D-binding protein isotypes 1 and 2 were significantly reduced in BRCA1 mutation carriers with respect to non-mutant controls. Only apolipoprotein A-IV plasma levels were significantly higher in cancer-free BRCA1 mutations carriers compared with BRCA1 mutations carriers who developed breast cancer.
Conclusion
It is suggested that independently of breast cancer generation, BRCA1-encoded gene alterations are associated with changes in the expression of circulating proteins associated with thrombosis and coagulation.
Similar content being viewed by others
References
Alonso-Orgaz S, Moreno L, Macaya C, Rico L, Mateos-Cáceres PJ, Sacristán D, Pérez-Vizcaíno F, Segura A, Tamargo J, López-Farré A (2006) Proteomic study of plasma from moderate hypercholesterolemic patients. J Proteome Res 5:2301–2308. doi:10.1021/pr060159w
Berstein LM, Koskela A, Boyarkina MP, Adlercreutz H (2010) Excretion of estrogens, catecholestrogens and phytoestrogens in carriers of BRCA1 gene mutations: effects of metformin. Neoplasma 57:333–338. doi:10.4149/neo_2010_04_333
Bick RL (2003) Cancer-associated thrombosis. N Engl J Med 349:109–111
Bombeli T, Schwartz BR, Harlan JM (1998) Adhesion of activated platelets to endothelial cells: evidence for a GPIIbIIIa-dependent bridging mechanism and novel roles for endothelial intercellular adhesion molecule 1 (ICAM-1), alphavbeta3 integrin, and GPIbalpha. J Exp Med 187:329–339. doi:10.1084/jem.187.3.329
Bourdeanu L, Luu T (2010) Arterial thrombosis associated with adjuvant chemotherapy for breast cancer: a case report. J Am Acad Nurse Pract 22:140–143. doi:10.1111/j.1745-7599.2009.00486.x
Brody LC, Biesecker BB (1998) Breast cancer susceptibility genes. BRCA1 and BRCA2. Medicine (Baltimore) 77:208–226
Bucurenci N, Blake DR, Chidwick K, Winyard PG (1992) Inhibition of neutrophil superoxide production by human plasma a1-antitrypsin. FEBS Lett 300:321. doi:10.1016/0014-5793(92)80156-B
Buller HR, van Doormaal FF, van Sluis GL, Kamphuisen PW (2007) Cancer and thrombosis: from molecular mechanisms to clinical presentations. J Thromb Haemost 1(Suppl):246–254. doi:10.1111/j.1538-7836.2007.02497.x
Chen S, Parmigiani G (2007) Meta-analyisis of BRCA1 and BRCA2 penetrance. J Clin Oncol 25:1329–1333. doi:10.1200/JCO.2006.09.1066
de la Hoya M, Pérez-Segura P, Van Orsouw N, Díaz-Rubio E, Caldés T (2001) Spanish family study on hereditary breast and/or ovarian cancer: analysis of the BRCA1 gene. Int J Cancer 91:137–140. doi:10.1002/10970215(20010101)91:1<137:AID-IJC1020>3.0.CO;2-R
de la Hoya M, Osorio A, Godino J, Sulleiro S, Tosar A, Perez-Segura P, Fernandez C, Rodríguez R, Díaz-Rubio E, Benítez J, Devilee P, Caldés T (2002) Association between BRCA1 and BRCA2 mutations and cancer phenotype in Spanish breast/ovarian cancer families: implications for genetic testing. Int J Cancer 97:466–471. doi:10.1002/ijc.1627
Defeo K, Hayes C, Chernick M, Van Ryn J, Gilmour SK (2010) Use of dabigatran etexilate to reduce breast cancer progression. Cancer Biol Ther. doi:10.4161/cbt.10.10.13236
Deng CX (2006) BRCA1: cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution. Nucleic Acids Res 34:1416–1426. doi:10.1093/nar/gkl010
Dieplinger H, Ankerst DP, Burges A, Lenhard M, Lingenhel A, Fineder L, Buchner H, Stieber P (2009) Afamin and apolipoprotein A-IV: novel protein markers for ovarian cancer. Cancer Epidemiol Biomarkers Prev 18:1127–1133. doi:10.1158/1055-9965.EPI-08-0653
Ford D, Easton DF, Peto J (1995) Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet 57:1457
Gailani D, Renné T (2007) Intrinsic pathway of coagulation and arterial thrombosis. Arterioscler Thromb Vasc Biol 27:2507–2513
Gast MC, Schellens JH, Beijnen JH (2009) Clinical proteomics in breast cancer: a review. Breast Cancer Res Treat 116:17–29. doi:10.1007/s10549-008-0263-3
Guo Q, Zhang B, Dong X, Wu Y (2009) Elevated levels of plasma fibrinogen in patients with pancreatic cancer: possible role of a distant metastasis predictor. Pancreas 38:75–79. doi:10.1097/MPA.0b013e3181987d86
Haddad TC, Greeno EW (2006) Chemotherapy-induced thrombosis. Thromb Res 118:555–568
Haiman M, Salvenmoser W, Scheiber K, Lingenhel A, Rudolph C, Schmitz G, Kronenberg F, Dieplinger H (2005) Immunohistochemical localization of apolipoprotein A-IV in human kidney tissue. Kidney Int 68:1130–1136. doi:10.1111/j.1523-1755.2005.00519.x
Hall JM, Lee MK, Newman B, Morrow JE, Anderson LA, Huey B, King MC (1990) Linkage of early-onset familial breast cancer to chromosome 17q21. Science 250:1684–1689
Hlavaty JJ, Partin AW, Shue MJ, Mangold LA, Derby J, Javier T, Kelley S, Stieg A, Briggman JV, Hass GM, Wu YJ (2003) Identification and preliminary clinical evaluation of a 50.8-kDa serum marker for prostate cancer. Urology 61:1261–1265. doi:10.1016/S0090-4295(03)00036-0
Jones JM, McGonigle NC, McAnespie M, Cran GW, Graham AN (2006) Plasma fibrinogen and serum C-reactive protein are associated with non-small cell lung cancer. Lung Cancer 53:97–101. doi:10.1016/j.lungcan.2006.03.012
Kennedy RD, Quinn JE, Johnston PG, Harkin DP (2002) BRCA1: mechanisms of inactivation and implications for management of patients. Lancet 360:1007–1014. doi:10.1016/S0140-6736(02)11087-7
Kinoshita T (1991) Biology of complement: the overture. Immunol Today 12:291–295
Koomen JM, Shih LN, Coombes KR, Li D, Xiao LC, Fidler IJ, Abbruzzese JL, Kobayashi R (2005) Plasma protein profiling for diagnosis of pancreatic cancer reveals the presence of host response proteins. Clin Cancer Res 11:1110–1118
Kumar K, Thangaraju M, Sachdanandam P (1991) Changes observed in antioxidant system in the blood of postmenopausal women with breast cancer. Biochem Int 25:371–380
Li J, Zhang Z, Rosenzweig J, Wang YY, Chan DW (2002) Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 48:1296–1304
Li J, Orlandi R, White CN, Rosenzweig J, Zhao J, Seregni E, Morelli D, Yu Y, Meng XY, Zhang Z, Davidson NE, Fung ET, Chan DW (2005) Independent validation of candidate breast cancer serum biomarkers identified by mass spectrometry. Clin Chem 51:2229–2235
López-Farré A, Zamorano-León JJ (2010) The contribution of proteomics to cancer diagnosis. Cancer Chemother 5:167–176
López-Farré AJ, Mateos-Cáceres PJ, Sacristán D, Azcona L, Bernardo E, de Prada TP, Alonso-Orgaz S, Fernández-Arquero M, Fernández-Ortiz A, Macaya C (2007) Relationship between vitamin D binding protein and aspirin resistance in coronary ischemic patients: a proteomic study. J Proteome Res 6:2481–2487. doi:10.1021/pr060600i
Mannucci PM (1995). Recent progress in the pathophysiology of fibrinogen. Eur Heart J 16(Suppl A):25–30. doi:10.1093/eurheartj/16.suppl_A.25
Mateos-Cáceres PJ, García-Méndez A, López Farré A, Macaya C, Núñez A, Gómez J, Alonso-Orgaz S, Carrasco C, Burgos ME, de Andrés R, Granizo JJ, Farré J, Rico LA (2004) Proteomic analysis of plasma from patients during an acute coronary syndrome. J Am Coll Cardiol 44:1578–1583. doi:10.1016/j.jacc.2004.06.073
Mateos-Cáceres PJ, Macaya C, Azcona L, Modrego J, Mahillo E, Bernardo E, Fernandez-Ortiz A, López-Farré AJ (2010) Different expression of proteins in platelets from aspirin-resistant and aspirin-sensitive patients. Thromb Haemost 103:160–170. doi:10.1160/TH09-05-0290
McEachron TA, Pawlinski R, Richards KL, Church FC, Mackman N (2010) Protease-activated receptors mediate cross-talk between coagulation and fibrinolysis. Blood 116:5037–5044. doi:10.1182/blood-2010-06-293126
Mego M, De Giorgi U, Broglio K, Dawood S, Valero V, Andreopoulou E, Handy B, Reuben JM, Cristofanilli M (2009) Circulating tumour cells are associated with increased risk of venous thromboembolism in metastatic breast cancer patients. Br J Cancer 101:1813–1816. doi:10.1038/sj.bjc.6605413
Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran CL, Bennett M, Ding W, Bell R, Rosenthal J, Hussey C, Tran T, McClure M, Frye C, Hattier T, Phelps R, Haugen-Strano A, Katcher H, Yakumo K, Gholami Z, Shaffer D, Stone S, Bayer S, Wray C, Bogden R, Dayananth P, Ward J, Tonin P, Narod S, Bristow PK, Norris FH, Helvering L, Morrison P, Rosteck P, Lai M, Barrett JC, Lewis C, Neuhausen S, Cannon-Albright L, Goldgar D, Wiseman R, Kamb A, Skolnick MH (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66–71
Miller VM, Jayachandran M, Heit JA, Owen WG (2006) Estrogen therapy and thrombotic risk. Pharmacol Ther 111:792–807
Modrego J, Maroto L, Tamargo J, Azcona L, Mateos-Cáceres P, Segura A, Moreno-Herrero R, Pérez-Castellanos N, Delpón E, Pérez-Villacastín J, Rodríguez E, Macaya C, López-Farré AJ (2010) Comparative expression of proteins in left and right atrial appendages from patients with mitral valve disease at sinus rhythm and atrial fibrillation. J Cardiovasc Electrophysiol 21:859–868. doi:10.1111/j.1540-8167.2010.01718.x
Nagulu M, Uday KV, Nalini K, Dharak R, Narsimha RY, Rama KD (2009) Oxidative stress and anti-oxidant status in breast cancer patients. J Pharm Res 2:62–65
Nand S (1993) Homeostasis and cancer. Cancer J 6:54–58
Osborne CK (1998) Tamoxifen in the treatment of breast cancer. N Engl J Med 339:1609–1618
Ostos MA, Conconi M, Vergnes L, Baroukh N, Ribalta J, Girona J, Caillaud JM, Ochoa A, Zakin MM (2001) Antioxidative and antiatherosclerotic effects of human apolipoprotein A-IV in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Bio 21:1023–1028. doi:10.1161/01.ATV.21.6.1023
Polterauer S, Grimm C, Seebacher V, Concin N, Marth C, Tomovski C, Husslein H, Leipold H, Hefler-Frischmuth K, Tempfer C, Reinthaller A, Hefler L (2009) Plasma fibrinogen levels and prognosis in patients with ovarian cancer: a multicenter study. Oncologist 14:979–985. doi:10.1634/theoncologist.2009-0079
Punnonen K, Ahotupa M, Asaishi K, Hyöty M, Kudo R, Punnonen R (1994) Antioxidant enzyme activities and oxidative stress in human breast cancer. J Cancer Res Clin Onco 120:374–377. doi:10.1007/BF01247464
Qin X, Swertfeger DK, Zheng S, Hui DY, Tso P (1998) Apolipoprotein AIV: a potent endogenous inhibitor of lipid oxidation. Am J Physiol 274:H1836–H1840
Rickles FR, Edwards RL (1983) Activation of blood coagulation in cancer: Trousseau’s syndrome revisited. Blood 62:14–31
Rosenberg RD, Aird WC (1999) Vascular-bed-specific hemostasis and hypercoagulable states. N Engl J Med 340:1555–1564
Sahni A, Simpson-Haidaris PJ, Sahni SK, Vaday GG, Francis CW (2008) Fibrinogen synthesized by cancer cells augments the proliferative effect of fibroblast growth factor2 (FGF-2). J Thromb Haemost 6:174–175. doi:10.1111/j.1538-7836.2007.02808.x
Saphner T, Tormey DC, Gray R (1991) Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol 9:286–294
Talmud PJ, Martin S, Steiner G, Flavell DM, Whitehouse DB, Nagl S, Jackson R, Taskinen MR, Frick MH, Nieminen MS, Kesäniemi YA, Pasternack A, Humphries SE, Syvänne M (2003) Diabetes Atherosclerosis Intervention Study Investigators. Progression of atherosclerosis is associated with variation in the alpha1-antitrypsin gene. Arterioscler Thromb Vasc Biol 23:644–649. doi:10.1161/01.ATV.0000065196.61663.8D
Tesselaar ME, Ouwerkerk J, Nooy MA, Rosendaal FR, Osanto S (2004) Risk factors for catheter-related thrombosis in cancer patients. Eur J Cancer 40:2253–2259. doi:10.1016/j.ejca.2004.06.023
Tonin P, Weber B, Offit K, Couch F, Rebbeck TR, Neuhausen S, Godwin AK, Daly M, Wagner-Costalos J, Berman D, Grana G, Fox E, Kane MF, Kolodner RD, Krainer M, Haber DA, Struewing JP, Warner E, Rosen B, Lerman C, Peshkin B, Norton L, Serova O, Foulkes WD, Lynch HT, Lenoir GM, Narod SA, Garber JE (1996) Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nat Med 2:1179–1183
Trenz K, Lugowski S, Jahrsdörfer U, Jainta S, Vogel W, Speit G (2003) Enhanced sensitivity of peripheral blood lymphocytes from women carrying a BRCA1 mutation towards the mutagenic effects of various cytostatics. Mutat Res 544:279–288. doi:10.1016/j.mrrev.2003.06.011
Vasconcellos CA, Lind SE (1993) Coordinated inhibition of actin-induced platelet aggregation by plasma gelsolin and vitamin D-binding protein. Blood 82:3648–3657
Villanueva J, Shaffer DR, Philip J, Chaparro CA, Erdjument-Bromage H, Olshen AB, Fleisher M, Lilja H, Brogi E, Boyd J, Sanchez-Carbayo M, Holland EC, Cordon-Cardo C, Scher HI, Tempst P (2006) Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest 116:271–284. doi:10.1172/JCI26022
Zamorano-León JJ, Modrego J, Mateos-Cáceres PJ, Macaya C, Martín-Fernández B, Miana M, de las Heras N, Cachofeiro V, Lahera V, López-Farré AJ (2010) A proteomic approach to determine changes in proteins involved in the myocardial metabolism in left ventricles of spontaneously hypertensive rats. Cell Physiol Biochem 25:347–358
Zielinski CC, Budinsky AC, Wagner TM, Wolfram RM, Köstler WJ, Kubista M, Brodowicz T, Kubista E, Wiltschke C (2003) Defect of tumour necrosis factor-alpha (TNF-alpha) production and TNF-alpha-induced ICAM-1-expression in BRCA1 mutations carriers. Breast Cancer Res Treat 81:99–105
Acknowledgments
This work has been supported by a grant from Oncology Spanish Society, Fondos de Investigaciones de la Seguridad Social (Redes Temáticas de Cooperación Red Heracles RD06/0009010 and Redes Temáticas Investigación y Cooperación en Cancer RD06/0020/0021). Petra J. Mateos-Cáceres is staff of Fundación para la Investigación Biomédica del Hospital Clínico San Carlos. José J Zamorano-León is staff of Red Heracles (Redes Temáticas de Cooperación Red Heracles RD06/0009/010). We thank Begoña Larrea for secretarial assistance.
Conflict of interest
All authors declare no conflicts of interest with respect to the manuscript entitled “Changes in the expression of plasma proteins associated with thrombosis in BRCA1 mutation carriers.”
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Custodio, A., López-Farré, A.J., Zamorano-León, J.J. et al. Changes in the expression of plasma proteins associated with thrombosis in BRCA1 mutation carriers. J Cancer Res Clin Oncol 138, 867–875 (2012). https://doi.org/10.1007/s00432-012-1161-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-012-1161-y